RE:onc Stop sowing doubt, we know your game very well. First, -40% of the share price of 1 month ago, it's a biased analysis. $3.39 is a maximum reached which lasted only a few days following the announcement concerning phase 3 with Pancan. This in no way reflects the average share price of the past year, which was regularly between $1 and $1.25. So the current price of $2 is +70% around the average of the last year. Regarding phase 3 with Pancan, it will be signed, don't try to mislead people on that either. If they made this important announcement, it's only a matter of weeks before it's done. And for the duration of the phase 3 clinical trials with Pancam, we will know more in the coming weeks/months.